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Objectives. To study plasma MMP-9 levels before and after carotid endarterectomy (CEA).
Design. Observational study.
Methods. Pre-operative (morning of surgery) and post-operative (48 h) plasma samples were obtained from 75 consecutive
patients undergoing CEA. MMP-9 concentrations were quantified using ELISA. Transcranial Doppler monitoring was
performed on each patient to detect particulate embolisation during the dissection phase of the CEA, until the application of
carotid clamps.
Results. The median post-operative plasma MMP-9 level of emboli-positive patients was significantly higher than their
median pre-operative value (14.9 ng/ml vs. 8.8 ng/ml; p ¼ 0.038). However, no significant difference was seen in the plasma
MMP-9 level of emboli-negative patients (7.7 ng/ml vs. 7.1 ng/ml; p ¼ 0.364). A greater rise was seen in the median plasma
MMP-9 levels of those patients suffering.2 emboli (from 3.4 to 19.3 ng/ml; p ¼ 0.041) than those patients suffering 1 or 2
emboli (from 10.1 to 12.8 ng/ml; p ¼ 0.340).
Conclusions. Plasma MMP-9 only rises after CEA in patients with evidence of embolisation. This increase is more
pronounced in those with high numbers of emboli. These data suggest that the increase in MMP-9 is due to cerebral damage
caused by embolisation.
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Introduction
Matrix metalloproteinases (MMPs) are a family of
proteolytic enzymes responsible for degradation of the
extracellular matrix.1 The MMPs play an integral part
in acute disruption of the atherosclerotic plaque,2,3
which precedes stroke and myocardial infarction.4 Of
particular interest is MMP-9, which exhibits increased
levels and activity in unstable coronary5 and carotid6
plaques. MMP activity is tightly regulated in vivo and
the major inhibitor of MMP-9 is tissue inhibitor of
metalloproteinase-1 (TIMP-1).
Patients with significant carotid stenoses in whom
spontaneous cerebral embolisation is detected exhibit
raised levels of plasma MMP-9.7 The source of this
MMP-9 is unknown. It may reflect a systemic
manifestation of increased local synthesis within the
carotid plaque, (Fig. 1) and possibly multiple other
plaques throughout the vascular tree. Alternatively,
plasma MMP-9 may arise from circulating neutrophils
and monocytes (Fig. 2)—there is mounting evidence to
suggest a causal role for systemic inflammation in
plaque destabilisation.8 Finally, it may represent
inflammation secondary to cerebral damage caused
by embolisation from the plaque (Fig. 3).
The aim of this study was to quantify plasma MMP-
9 and TIMP-1 levels before and after carotid endarter-




The local research ethics committee approved the
study and all patients gave informed written consent.
Pre-operatively, a detailed history was obtained from
each patient. The occurrence and timing (in relation to
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CEA) of carotid territory symptoms (transient ischae-
mic attack, amaurosis fugax, central retinal artery
occlusion or stroke) were noted. Patients suffering no
carotid territory symptoms within 6 months of surgery
were classified as asymptomatic. Demographic details
and risk factors for atherosclerosis were recorded. The
degree of carotid stenosis was assessed 24 h pre-
operatively by duplex ultrasound.
Plasma
Peripheral blood samples were obtained from 75
patients admitted to a single vascular unit for CEA
at the following two time-points—pre-operatively (on
the morning of surgery) and post-operatively (on the
morning of the second post-operative day). Samples
were collected in tubes containing EDTA and were
centrifuged at 2500 rpm for 10 min at 4 8C. Plasma was
then decanted into vials, which were ‘snap-frozen’ in
liquid nitrogen and stored at 280 8C. MMP-9 and
TIMP-1 concentrations were quantified by ELISA
(Amersham, UK).
Cerebral embolisation and operative procedure
Transcranial Doppler (TCD) monitoring of the middle
cerebral artery was performed on each patient during
two periods—a 30 min period 24 h prior to CEA, and
during the dissection phase of the procedure. A
standard technique was employed by each of the
four Consultant Surgeons operating on patients
enrolled in this study. This involved dissection of the
common carotid artery proximal to the carotid bulb,
followed by the internal carotid artery distal to the
plaque. This took place prior to clamping of the carotid
artery but involved minimal dissection of the diseased
segment. For the purpose of this study, recording was
discontinued upon clamping to ensure all recorded
emboli were due to dislodgement of particulate matter
from the plaque, rather than air or procedure-related
thrombus.9
Statistical analysis
The discrete variables (clinical characteristics, medi-
cation use, symptomatology) are presented as actual
numbers (and percentages) and compared using
Fisher’s exact test. The continuous variable of age
showed normal distribution. It is presented as a mean
value (and total range) and compared using the
parametric unpaired t-test. The other continuous
variables (severity of carotid stenosis, MMP-9 and
TIMP-1 concentration) did not show normal distri-
butions. They are presented as median values (and
Fig. 1. Possible sources of plasma MMP-9. From carotid
plaque, and possibly multiple other plaques throughout the
vascular tree.
Fig. 2. Possible sources of plasma MMP-9. From circulating
neutrophils and monocytes.
Fig. 3. Possible sources of plasma MMP-9. From cerebral
damage caused by embolisation from the plaque.
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interquartile ranges) and compared using the non-
parametric Mann–Whitney U-test. Significance is
assumed at the p , 0:05 level.
Results
Five patients were excluded from the study due to lack
of a TCD ‘window’ ðn ¼ 3Þ or patient refusal of the
post-operative blood sample ðn ¼ 2Þ: No patient
suffered a post-operative stroke.
Only four emboli (in three patients) were recorded
during the pre-operative 30 min period, and all three
of these patients also demonstrated dissection phase
embolisation. These groups were therefore analysed
together as ‘emboli-positive’, as the small number of
patients undergoing pre-operative embolisation pre-
cluded meaningful analysis at this time-point.
Of the 70 patients analysed, a total of 49 emboli
were detected in 15 patients during the dissection
phase. Symptomatic patients, and those with tighter
carotid stenoses, were more likely to be emboli-
positive (Table 1). There was a trend towards
decreased statin use in the emboli-positive patients,
though this did not reach significance. The groups
were otherwise comparable.
For the 15 emboli-positive patients, the median
post-operative plasma MMP-9 level was significantly
higher than the median pre-operative value
(14.9 ng/ml vs. 8.8 ng/ml; p ¼ 0:038). However, no
significant change was seen in the plasma MMP-9
level of the 55 emboli-negative patients (7.7 ng/ml vs.
7.1 ng/ml; p ¼ 0:364) (Fig. 4).
Comparison of pre-operative MMP-9 levels showed
no difference between emboli-positive and emboli-
negative groups. However, the post-operative values
were significantly higher in the emboli-positive group
(Table 2).
There were no changes in TIMP-1 concentrations
between the pre-operative and post-operative samples
in either the emboli-positive or emboli-negative
groups, nor when comparing the two groups at the
pre-operative and post-operative stages (Table 3).
On sub-analysis of the emboli-positive group, a
significantly greater rise in plasma MMP-9 levels was
demonstrated in the six patients with more than two
emboli detected (Fig. 5).
Discussion
We have previously demonstrated increased plasma
MMP-9 levels in patients awaiting carotid endarter-
ectomy in whom spontaneous particulate embolisa-
tion was detected by transcranial Doppler.7 In that
study, no difference in the level of TIMP-1 was
observed, suggesting a shift in the balance of circulat-
ing enzymes towards proteolysis—a process which is
normally under tight control. What was unclear from
this previous study was the origin of the increase in
systemic MMP-9.
The intraplaque level, expression and activity of
MMP-9 are significantly higher in unstable carotid
plaques (based on symptoms, embolisation and
histology).6 The plasma level of MMP-9 may reflect
this localised increase in activity, or may perhaps be a
sign of a generalised increase in tandem with a
systemic inflammatory response promoting plaque
degradation. Alternatively, it may be due to cerebral
ischaemia caused by particulate embolisation from the
plaque.
The present study demonstrated a significant rise in
plasma MMP-9 after surgery in patients with evidence
Table 1. Comparison of patient characteristics between emboli groups
Emboli-positive ðn ¼ 15Þ Emboli-negative ðn ¼ 55Þ p-Value
Mean age (range) 68.1 (59–80) 71.0 (50–86) 0.176
Male sex (%) 10 (67) 38 (69) 1.000
Ever smoker (%) 11 (73) 42 (76) 1.000
IHD (%) 4 (27) 23 (42) 0.376
BP (%) 9 (60) 37 (67) 0.760
DM (%) 2 (13) 11 (20) 0.720
Aspirin use (%) 15 (100) 49 (89) 0.329
Statin use (%) 6 (40) 34 (62) 0.152
% Stenosis (IQR) 85 (80–90) 80 (70–90) 0.019*
Symptomatic (%) 15 (100) 30 (55) 0.001*
Ever smoker, past or present history of smoking; IHD, ischaemic heart disease (history of MI, or angina requiring medication); BP,
hypertension (requiring medication); DM, diabetes mellitus (requiring long-term intervention including dietary modification); Carotid
stenosis, median duplex ultrasound estimate of carotid stenosis severity (%); Emboli-positive, one or more embolus detected during pre-
operative or dissection phase prior to carotid artery clamping; IQR, interquartile range; Symptomatic, carotid territory symptoms in 6 months
prior to surgery. p-Values calculated using unpaired t-test for mean age, Mann–Whitney U-test for carotid stenosis and Fisher’s exact test for
the rest. *Significant.
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of embolisation in the dissection phase of their
procedure (between the pre-operative and post-
operative blood samples). Those with no emboli
detected showed no change in plasma MMP-9 levels.
The rise in MMP-9 was more marked in those patients
with greater than two emboli detected. This suggests
an association between plasma MMP-9 levels and
cerebral embolisation rather than a phenomenon
related to localised increased plaque production or
generalised inflammation.
Human post-mortem studies have shown increased
cerebral MMP-9 levels in association with an intense
inflammatory reaction following stroke.10 Animal
models of cerebral ischaemia have demonstrated an
increase in cerebral MMP-9 with ischaemic injury.11
Further in vivo studies have shown an increase in
plasma MMP-9 levels in a rat model of middle cerebral
artery occlusion.12
Kai et al. reported raised peripheral blood levels
of MMP-9 in patients with acute coronary syn-
dromes.13 Early and significant increases in circulat-
ing MMP-9 were demonstrated in patients with
unstable angina/MI compared to stable angina and
normal controls. The authors failed to show an
association with CK or CK-MB isoforms, and there-
fore suggested the rise in MMP-9 was unlikely to be
secondary to end-organ myocardial ischaemia.
However, it should be recognised that CK and
CK-MB do not correlate well with the volume of
myocardial damage,14 and the number of patients in
the study was small.
A more recent study of 1127 patients with coronary
artery disease identified baseline plasma MMP-9
levels to be a novel predictor of cardiovascular
mortality.15 The MMP-9 levels correlated with other
Fig. 4. Graph demonstrating significant rise in plasma MMP-
9 levels in emboli-positive (red) but not emboli-negative
(blue) patients.
Table 2. Comparison of plasma MMP-9 concentrations between emboli groups
MMP-9 (ng/ml) Pre-operative plasma Post-operative plasma p-Value
Emboli-negative ðn ¼ 55Þ 7.1 (4.1–13.5) 7.7 (4.2–21.0) 0.364
Emboli-positive ðn ¼ 15Þ 8.8 (3.4–20.0) 14.9 (9.0–28.6) 0.038*
p-Value 0.506 0.025*
MMP-9 concentrations shown as median values (and interquartile ranges) in ng/ml of plasma. p-Values calculated using Mann–Whitney U-
test. *Significant.
Fig. 5. Graph demonstrating larger rise in plasma MMP-9
levels of patients with three or more emboli (red) compared
to those with one or two emboli (blue).
Table 3. Comparison of plasma TIMP-1 concentrations between emboli groups
TIMP-1 (ng/ml) Pre-operative plasma Post-operative plasma p-Value
Emboli-negative ðn ¼ 55Þ 967 (875–1084) 1033 (840–1243) 0.324
Emboli-positive ðn ¼ 15Þ 1011 (884–1105) 1046 (795–1269) 0.934
p-Value 0.534 0.937
TIMP-1 concentrations shown as median values (and interquartile ranges) in ng/ml of plasma. p-Values calculated using Mann–Whitney U-
test. *Significant.
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acute phase reactants, suggesting a link with a more
generalised inflammatory response.
Clearly further work is required to fully understand
the reasons for, and consequences of, this rise in
plasma MMP-9. An increase in systemic MMP-9 has
been shown within 12 h of cardioembolic stroke,16 and
it would be interesting to quantify the plasma MMP-9
levels earlier in the CEA post-operative period, and
later following discharge to establish the time course
of a return to normal levels. CT scans were not
performed in our study because previous studies
have reported a poor association between embolic
end-organ damage and CT changes.17 Psychometric
testing18 or magnetic resonance angiography19 may be
more sensitive markers of embolic damage, and could
be employed to confirm its association with the rise in
MMP-9 levels.
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